Kazım BEŞİRLİ, A. Kürşat BOZKURT, Caner ARSLAN, Hasan TÜZÜN, Gökçe ŞİRİN, Karman KAZIMOĞLU, Cengiz KÖKSAL, Kamil KAYNAK

Aterosklerotik damar hastalarında lipid ve lipoprotein değerlerinin irdelenmesi

Aterosklerotik arter hastalıklarında risk fak¬törleri iskemik kalp hastalıklarından farklı ola¬bilir. Çalışmamızda cerrahi endikasyon bulu¬nan 100 aterosklerotik damar hastasında lipid ve lipoprotein değerleri incelendi. Ortalama değerler göz önüne alındığında total kolesterol seviyesinin normalin üzerinde, apolipoprotein B değerlerinin normalin altında olduğu saptan¬dı. Bu nedenle, antilipidemik tedavinin atero¬sklerotik damar hastalarında hastalığın ortaya çıkışını engelleme ve seyrini yavaşlatmada et¬kili olacağını düşünüyoruz.

Evaluation of lipid and lipoprotein levels in patients with atherosclerotic vascular disease

Background and Design.- The risk factors in atherosclerotic vascular disease may be different from the ones in ischemic heart diseases. In our study, the levels of lipids and lipoproteins in 100 patients with atherosclerotic vascular disease who were candidate for surgery were evaluated. Results.- When average values were considered, the major finding was that total cholesterol levels were higher and apolipoprotein B levels were lower than normal. Conclusion.- We think that antilipidemic treatment is effective in preventing development and slowing the progress of atherosclerotic vascular disease.

PDF

___

1. Goldstein JL, Kita T, Brown MS: Defective lipoprotein receptors and atherosclerosis: Lessons from an animal counterpart of familial hypercholesterolemia. N Engl J Med 1983; 309: 288-296. 2. Tyroler HA: Review of lipid-lowering clinical trials in relation to observational epidemiologic studies. Circulation 1987; 76:515-522. 3. Miller GJ, Miller NE: Plasma high-density lipoprotein concentration and development of ischemic heart disease. Lancet 1975; 1:16-19. 4. Gordon DJ, Rifkind BM: High density lipoprotein: The clinical implication of recent studies. N Engl J Med. 1989; 321:1511-1316. 5. Vogelberg KH, Grimm K, Gries FA: Hypertriglyceridemia in insulin dependent diabetes mellitus with peripheral vascular disease. Horm Metab Res. 1995;15 (suppl): 90-94. 6. Dileğe Ş, Kayabalı M, Genç FA, Başar Y, Özgür M: Aterosklerotik tıkayıcı periferik damar hastalıklarında kolestrol profili. Damar Cerrahisi Dergisi 1993 ;3:127-130. 7. Hughson WG, Mann JL, Garrod A: Intermittant claudication; prevalence and risk factors. Br J Med 1978;1: 1379-1381. 8. Lawn RM, Berg K: Lipoprotein (a) and atherosclerosis. Annals of Int Med 1991; 115: 209- 218. 9. Drexel H, Steurer J, Muntwyler J, Meinenberg S, Schmid HR, Shneider E, Gröchenig E, Amann FW: Predictors of the precence and extend of peripheral arterial occlusive disease. Circulation 1996;94 (suppl II): 199-205 10. Tokgözoğlu L: Türklerde kolesterol ve trigliseridler. TEKHARF:Türk erişkinlerinde kalp sağlığının dünü ve bugünü. Ed. Onat A, Avcı GŞ, Soydan İ, Koylan N, Sansoy V, Tokgözoğlu L. İstanbul, 1996;45-62. 11. Smith I, Franks PJ, Greenhalgh RM, Poulter NR, Powell JT:The influence of smoking cessation and hypertriglyceridaemia on the progression of peripheral arterial disease and the onset of critical ischaemia. Eur J Vase Endovasc Surg 1996; 11: 402-408. I 12. Price JF, Lee AJ, Rumley A, Lowe GD, Fowkes FG: Lipoprotein (a) and development of intermittent claudication and major cardiovascular events in men and women: The Edinburgh Artery Study. Atherosclerosis 2001; 157: 241 -249 13. Howes LG, Abbott D, Straznicky NE: Lipoproteins and cardiovascular reactivity. Br J Clin Pharmocol 1997; 44: 319-324. 14. Dixon JL, Stoops JD, Parker JL, Laüghlin MH, Weisman GA, Sturek M: Dyslipidemia and vascular dysfunction in diabetic pigs fed an atherogenic diet. Arterioscler Thromb Vase Biol 1999; 19:2981-2992.